Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Personal financial planning is vital for achieving long-term financial goals. Learn why it matters and how to get started effectively.
24,448 articlesTeva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Retail buyers piled into SpaceX shares over a two-day window, creating a record pace that outstripped every other U.S...
A landmark housing bill cleared Congress this week, promising to ease rents and expand homebuilding. President Trump ...
Chicago-based MLS operator MRED formally pushes to compel arbitration with Zillow, placing a spotlight on contract la...
In this in-depth piece, we explore Mamoon Hamid’s approach to AI investing at Kleiner Perkins, the lessons from early...
NVIDIA’s push beyond chips is drawing investor attention to life sciences. This article breaks down what Jensen Huang...
A single chokepoint can reshape markets. When the strait hormuz closure sent oil prices higher, energy shares jumped ...
VanEck's NLR ETF blends uranium miners, enrichers and reactor operators, trading at 0.61%, as investors seek a balanc...
Cogent Biosciences has delivered staggering gains in a single year, yet a major fund recently trimmed its stake by mi...
New York Governor Hochul’s decision to pause autonomous for-hire vehicle expansion outside NYC hits Waymo and Tesla’s...
Microsoft reported a sharp jump in capital spending as it doubles down on AI infrastructure. Four-quarter CapEx now t...
Nvidia is reportedly developing a chip platform focused on AI inference workloads amid a shift in the AI landscape. E...